Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | STS | P08842 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31339498 | 1.00 | EPHX1 (0.45) | EPHX1CA1CA2CA12CA9 | |
| SCHEMBL31339503 | 1.00 | EPHX1 (0.45) | EPHX1CA1CA2CA12CA9 | |
| SCHEMBL1334650 | 0.98 | EPHX1 (0.42) | EPHX1CA1CA2CA12CA9 | |
| SCHEMBL28286386 | 0.93 | — | — | |
| SCHEMBL28104542 | 0.88 | — | — | |
| SCHEMBL17681940 | 0.82 | SERPINE1 (0.31) | — | |
| SCHEMBL2531983 | 0.81 | EPHX1 (0.48) | EPHX1CA1CA2CA12CA9 | |
| SCHEMBL733037 | 0.79 | EPHX1 (0.47) | EPHX1CA1CA2CA12CA9 | |
| SCHEMBL2528803 | 0.78 | EPHX1 (0.45) | EPHX1CA1CA2CA12CA9 | |
| SCHEMBL11473389 | 0.77 | EPHX1 (0.45) | EPHX1CA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0843220-B1 | Radiation sensitive resin composition | JSR CORP (JP) | 2003-02-19 | — | — | EP | claimed |
| EP-1087977-B1 | THIENODIPYRIDINE DERIVATIVES, PRODUCTION AND USE THEREOF | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-01-08 | — | — | EP | claimed |
| US-4098997-A | REACTION WITH PROPIOLIC ACID ESTERS | NATIONAL STARCH AND CHEMICAL CORPORATION (US) | 1978-07-04 | — | — | US | claimed |
| CN-119285565-A | Melamine monoamine ester derivative and preparation method thereof | 四川金象赛瑞化工股份有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-116134060-B | Method for producing aqueous dispersion of fluoroelastomer, and aqueous dispersion | 大金工业株式会社 | 2024-06-18 | — | — | CN | disclosed |
| CN-117529511-A | Method for producing aqueous dispersion of fluoroelastomer, composition, and aqueous dispersion | 大金工业株式会社 | 2024-02-06 | — | — | CN | disclosed |
| CN-117015557-A | Process for producing fluororesin, and aqueous dispersion | 大金工业株式会社 | 2023-11-07 | — | — | CN | disclosed |
| CN-116134060-A | Method for producing aqueous dispersion of fluoroelastomer, and aqueous dispersion | 大金工业株式会社 | 2023-05-16 | — | — | CN | disclosed |
| CN-111732504-A | Preparation method for synthesizing propiolic acid and derivatives thereof | 西南科技大学 | 2020-10-02 | — | — | CN | disclosed |
| CN-108424367-B | Method for preparing propiolic acid and derivatives thereof under mild condition | 中国科学院化学研究所 | 2020-08-18 | — | — | CN | disclosed |
| CN-108424367-A | A kind of method that propiolic acid and its derivative are prepared under temperate condition | 中国科学院化学研究所 | 2018-08-21 | — | — | CN | disclosed |
| US-8513230-B2 | Nuclear transport modulators and uses thereof | KARYOPHARM THERAPEUTICS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513230-B2 | Nuclear transport modulators and uses thereof | KARYOPHARM THERAPEUTICS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20110275607-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275607-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| WO-2011109799-A1 | NUCLEAR TRANSPORT MODULATIORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
| EP-0893451-B1 | Polysaccharide modification in densified fluid | NAT STARCH CHEM INVEST (US) | 2005-03-02 | — | — | EP | disclosed |
| US-5977348-A | ESTERIFYING OR ETHERIFYING POLYSACCHARIDE BY MIXING WITH REAGENT UNDER DENSIFIED FLUID UP TO 15% WATER BY VOLUME FOR PERIOD OF TIME; FOR HIGH DEGREE OF SUBSTITUTION WITHOUT USE OF TRADITIONAL ORGANIC SOLVENTS OR REPEATED REACTIONS | NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0893451-A2 | Polysaccharide modification in densified fluid | National Starch and Chemical Investment Holding Corporation (US) | 1999-01-27 | — | — | EP | disclosed |
| US-4098997-A | REACTION WITH PROPIOLIC ACID ESTERS | NATIONAL STARCH AND CHEMICAL CORPORATION (US) | 1978-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275607-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, NXF1, XPOT | EPHX1 4325/4885CA1 4489/4885CA2 2973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.